Aurobindo Pharma Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 14,77,984 shares,. Its Average Traded Price (ATP) is ₹1817.56, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 415 @ ₹1794.00.
Aurobindo Pharma has an upper circuit limit of ₹2005.50 and a lower circuit limit of ₹1640.90. The total value traded stands at ₹268.63 CR, and the delivery percentage for the day is 46.47%.
The stock is currently traded with a market lot size of 1. Aurobindo Pharma also offers a dividend yield of 0.22%.
Aurobindo Pharma Share Price Chart
Aurobindo Pharma Share Key Metrics
Volume
14.78 L
Market Cap
103222.79 CR
LTQ@LTP
415@1794.00
ATP
1817.56
Var Margin
14.2 %
Circuit Range
1640.9-2005.5
Delivery %
46.47 %
Value
268.63 CR
ASM/GSM
No
Market Lot
1
Aurobindo Pharma Resistance and Support
Pivot 1818.57
Resistance
First Resistance
1837.04
Second Resistance
1850.87
Third Resistance
1869.34
Support
First Support
1804.74
Second Support
1786.27
Third Support
1772.44
Aurobindo Pharma Futures & Options
1794
-29.2 (-1.6%)
Aurobindo Pharma Option Chain
View Price, OI, Greeks & More...
23NOV26
1790.30
-29.30 (1.61%)
29DEC26
1808.00
-22.40 (1.22%)
25JAN27
1811.40
-27.80 (1.51%)
AUROPHARMA|23NOV26 CE 1780.00
31.50
-22.1 (-41.23%)
AUROPHARMA|23NOV26 PE 1800.00
28.6
7.5 (35.55%)
Aurobindo Pharma Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Aurobindo Pharma Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-04 | Quarterly Results & Interim Dividend |
| 2026-08-05 | Quarterly Results |
| 2026-05-21 | Audited Results |
| 2026-04-06 | Buy Back of Shares |
| 2026-02-09 | Quarterly Results |
| 2025-11-05 | Quarterly Results |
| 2025-08-04 | Quarterly Results & Interim Dividend |
| 2025-05-26 | Audited Results |
| 2025-02-06 | Quarterly Results |
| 2024-11-09 | Quarterly Results |
| 2024-08-10 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-11-11 | 2026-11-11 | View More |
| Buyback Period | ||
|---|---|---|
| 5 Aug - 09 Aug 24 12.30 pm | View More |
Aurobindo Pharma News
Aurobindo Pharma Ltd - 524804 - Apitoria Unit 2, An API Manufacturing Facility Of Apitoria Pharma Private Limited., A Subsidiary Of The Company, Receives Establishment Inspection Report From US FDA With Classification As 'Voluntary Action Indicated'
Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma, has received an Establishment Inspection Report (EIR) from the US FDA for its API facility (Unit-II) in Telangana. The FDA classified the facility as 'Voluntary Action Indicated' (VAI) and closed the inspection conducted in September 2026.
Nov 11 2026 11:34:09
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Restructuring
Aurobindo Pharma announced the Scheme of Amalgamation for the merger of its wholly-owned subsidiaries Auroactive Pharma and Apitoria Pharma. The consolidation aims to streamline the API business and optimize capacity utilization with no change in the listed entity's shareholding.
Nov 04 2026 20:28:24
Aurobindo Pharma Ltd - 524804 - Intimation Of Record Date For Payment Of Interim Dividend For FY 2026-2027.
Aurobindo Pharma has declared an interim dividend of ₹7 per equity share for FY27. The company fixed November 11 2026 as the record date, with the payout scheduled on or before November 20 2026.
Nov 04 2026 20:20:32
Aurobindo Pharma Ltd - 524804 - Corporate Action-Board approves Dividend
Aurobindo Pharma announced an interim dividend of ₹7.00 per share for FY 2026-27. The record date is set for November 11, 2026, and the payout will be completed on or before November 20, 2026.
Nov 04 2026 20:16:01
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aurobindo Pharma reported Q2 FY27 results with cons. revenue of Rs.10,263 crore, a 24% YoY increase. Net profit rose 32.5% YoY to Rs.1,124 crore, driven by US and Europe sales, alongside an interim dividend declaration of Rs.7 per share.
Nov 04 2026 20:03:15
Aurobindo Pharma Ltd - 524804 - Board Meeting Outcome for Outcome Of Board Meeting
Aurobindo Pharma reported Q2 FY27 cons. revenue of ₹10,227.28 crores (up 24.1% YoY) and net profit of ₹1,126.08 crores (up 32.7% YoY). The Board declared an interim dividend of ₹7 per share with a record date of November 11, 2026, and approved the amalgamation of its wholly-owned subsidiaries.
Nov 04 2026 19:59:48
Aurobindo Pharma Ltd - 524804 - Board Meeting Intimation for Intimation Of Board Meeting
Aurobindo Pharma's board will meet on 4 November 2026. The agenda includes financial results and consideration of an interim dividend for FY 2026-27.
Oct 26 2026 07:48:35
Aurobindo Pharma Management
| Name | Position |
|---|---|
| Mangalam Ramasubramanian Kumar | Chairman |
| K Nityananda Reddy | Vice Chairman & Managing Director |
Aurobindo Pharma Similar Stocks
Apollo Hospitals Enterprise Ltd.
8771.00
245.00 (2.87%)
Zydus Lifesciences Ltd.
1192.00
2.10 (0.18%)
Dr. Reddy's Laboratories Ltd.
1377.90
-2.10 (0.15%)
Cipla Ltd.
1394.50
2.70 (0.19%)
Mankind Pharma Ltd.
2626.60
-13.40 (0.51%)
Lupin Ltd.
1976.70
-3.60 (0.18%)
Max Healthcare Institute Ltd.
1009.90
62.80 (6.63%)
Manipal Health Enterprises Ltd.
691.25
9.85 (1.45%)
Glenmark Pharmaceuticals Ltd.
2632.90
-7.10 (0.27%)
Aster DM Quality Care Ltd.
750.00
27.50 (3.81%)
Aurobindo Pharma FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in AUROPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC
Or Download Choice FinX App
Invest in AUROPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade